×
Cronos Group Common Stock Net 2017-2025 | CRON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Cronos Group common stock net from 2017 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
Cronos Group Common Stock Net 2017-2025 | CRON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Cronos Group common stock net from 2017 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$82.5B
Zoetis (ZTS)
$65B
Daiichi Sankyo, - (DSNKY)
$47.2B
Takeda Pharmaceutical (TAK)
$45.4B
BeOne Medicines - (ONC)
$32.7B
Sandoz Group AG (SDZNY)
$24.6B
Summit Therapeutics (SMMT)
$21.2B
Merck (MKKGY)
$16B
Shionogi (SGIOY)
$15.1B
United Therapeutics (UTHR)
$13.6B
Neurocrine Biosciences (NBIX)
$12.7B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$10.1B
Madrigal Pharmaceuticals (MDGL)
$7.5B
Corcept Therapeutics (CORT)
$7.4B
Stevanato Group S.p.A (STVN)
$7.3B
Grifols, S.A (GRFS)
$7.2B
Ionis Pharmaceuticals (IONS)
$6.5B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.1B
Hypermarcas (HYPMY)
$2.8B
Crinetics Pharmaceuticals (CRNX)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.7B
NewAmsterdam Pharma (NAMS)
$2.7B
Procaps Group, S.A (PROCF)
$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.3B
Ocular Therapeutix (OCUL)
$2.2B
Endo (NDOI)
$1.8B